Data / Form D filings / Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc.: Form D filings
Matinas BioPharma Holdings, Inc., a biotechnology company in Bedminster, NJ, filed 6 Form D notices with the SEC between 2013 and 2025. The latest, on February 19, 2025, reports $1.7 million sold of a $3.3 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1545 ROUTE 206 SOUTH, SUITE 302, Bedminster, NJ, 07921
- Phone
- (908) 443-1860
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1582554
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | New notice | $3,300,000 | $1,650,000 | $1,650,000 | 4 | Feb 13, 2025 | sec.gov |
| Jan 26, 2017 | New notice | $15,483,175 | $15,483,175 | 270 | Jan 13, 2017 | sec.gov | |
| Aug 12, 2016 | New notice | $8,000,000 | $4,400,290 | $3,599,710 | 34 | Jul 29, 2016 | sec.gov |
| Apr 13, 2015 | New notice | $10,000,000 | $10,000,000 | 122 | Mar 31, 2015 | sec.gov | |
| Aug 7, 2013 | New notice | $15,000,000 | $7,593,750 | $7,406,250 | 52 | Jul 30, 2013 | sec.gov |
| Jul 25, 2013 | New notice | $385,000 | $385,000 | 31 | Jul 11, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Robin Smith | Director | |
| Eric Ende | Director | |
| Jerome Jabbour | Executive Officer, Director | |
| Evelyn D'An | Director | |
| Keith Kucinski | Executive Officer | |
| Matthew Wikler | Director | |
| Natasha Giordano | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Feb 17, 2025 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Matinas BioPharma Holdings, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.